1-Minute Consult

How should you assess glycemic control if the hemoglobin A1c is inaccurate or uninterpretable?

Wendy O. Henderson, MD, Mary H. Parker, PharmD, FASHP, FCCP, BCPS, BCCP and Bryan C. Batch, MD, MHS
Cleveland Clinic Journal of Medicine February 2021, 88 (2) 81-85; DOI: https://doi.org/10.3949/ccjm.88a.19135
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.

REFERENCES

  1. ↵
    1. NGSP
    . HbA1c assay interferences. Accessed January 22, 2021. http://www.ngsp.org/interf.asp.
  2. ↵
    1. Radin MS
    . Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med 2014; 29(2):388–394. doi:10.1007/s11606-013-2595-x
    OpenUrlCrossRefPubMed
    1. American Diabetes Association
    . 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care 2020; 43(suppl 1):S14–S31. doi:10.2337/dc20-S002
    OpenUrlAbstract/FREE Full Text
    1. Lacy ME,
    2. Wellenius GA,
    3. Sumner AE, et al
    . Association of sickle cell trait with hemoglobin A1c in African Americans. JAMA 2017; 317(5):507–515. doi:10.1001/jama.2016.21035
    OpenUrlCrossRef
    1. Blendea MC,
    2. Thompson MJ,
    3. Malkani S
    . Diabetes and chronic liver disease: etiology and pitfalls in monitoring. Clin Diabetes 2010: 28(4):139–144. doi:10.2337/diaclin.28.4.139
    OpenUrlFREE Full Text
  6. ↵
    1. Spencer DH,
    2. Grossman BJ,
    3. Scott MG
    . Red cell transfusion decreases hemoglobin A1c in patients with diabetes. Clin Chem 2011; 57(2):344–346. doi:10.1373/clinchem.2010.157321
    OpenUrlFREE Full Text
    1. Fayyaz B,
    2. Rehman HJ,
    3. Minn H
    . Interpretation of hemoglobin A1c in primary care setting. J Community Hosp Intern Med Perspect 2019; 9(1):18–21. doi:10.1080/20009666.2018.1559432
    OpenUrlCrossRef
  8. ↵
    1. Hellman R
    . When are HBA1c values misleading? AACE Clin Case Reports 2016; 2(4):e377–e379. doi:10.4158/EP161209.CO
    OpenUrlCrossRef
  9. ↵
    1. Nathan DM,
    2. Kuenen J,
    3. Borg R,
    4. Zheng H,
    5. Schoenfeld D,
    6. Heine RJ; A1c-Derived Average Glucose Study Group
    . Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31(8):1473–1478. doi:10.2337/dc08-0545
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. American Diabetes Association
    . eAG/A1C conversion calculator. Accessed January 22, 2021. https://professional.diabetes.org/diapro/glucose_calc
  11. ↵
    1. American Diabetes Association
    . 7. Diabetes technology: standards of medical care in diabetes—2020. Diabetes Care 2020; 43(suppl 1): S77–S88. doi:10.2337/dc20-S007
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Moser O,
    2. Pandis M,
    3. Aberer F, et al
    . A head-to-head comparison of personal and professional continuous glucose monitoring systems in people with type 1 diabetes: hypoglycaemia remains the weak spot. Diabetes Obes Metab 2019; 21(4):1043–1048. doi:10.1111/dom.13598
    OpenUrlCrossRef
  13. ↵
    1. Lee JE
    . Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol. Ann Pediatr Endocrinol Metab 2015; 20(2):74–78. doi:10.6065/apem.2015.20.2.74
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kunika K,
    2. Itakura M,
    3. Yamashita K
    . Correction of fructosamine value for serum albumin and globulin concentrations. Diabetes Res Clin Pract 1991; 13(1-2):37–44. doi:10.1016/0168-8227(91)90031-8
    OpenUrlCrossRefPubMed
  15. ↵
    1. Danese E,
    2. Montagnana M,
    3. Nouvenne A,
    4. Lippi G
    . Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol 2015; 9(2):169–176. doi:10.1177/1932296814567227
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kang DS,
    2. Park J,
    3. Kim JK,
    4. Yu J
    . Clinical usefulness of the measurement of serum fructosamine in childhood diabetes mellitus. Ann Pediatr Endocrinol Metab 2015; 20(1):21–26. doi:10.6065/apem.2015.20.1.21
    OpenUrlCrossRef
  17. ↵
    1. Koga M,
    2. Murai J,
    3. Morita S,
    4. Saito H,
    5. Kasayama S
    . Comparison of annual variability in HbA1c and glycated albumin in patients with type 1 vs. type 2 diabetes mellitus. J Diabetes Complications 2013; 27(3):211–213. doi:10.1016/j.jdiacomp.2012.12.001
    OpenUrlCrossRefPubMed
  18. ↵
    1. Buse JB,
    2. Freeman JL,
    3. Edelman SV,
    4. Jovanovic L,
    5. McGill JB
    . Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 2003; 5(3):355–363. doi:10.1089/152091503765691839
    OpenUrlCrossRefPubMed
  19. ↵
    1. Dungan KM
    . 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008; 8(1):9–19. doi:10.1586/14737159.8.1.9
    OpenUrlCrossRefPubMed
  20. ↵
    1. Kalra S
    . Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 2014; 5(2):355–366. doi:10.1007/s13300-014-0089-4
    OpenUrlCrossRefPubMed

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects